Compound library screens using 2D monolayer cancer-cell lines are commonly performed in the pharmaceutical industry to identify molecules with therapeutic potential. Multiple analogues and modified derivatives are generated and tested before candidates progress to clinical trials. This is a lengthy and costly process with a poor success rate. This is partly due to the failure of the current generation of preclinical cell-based assays to accurately predict clinical efficacy.
3D patient-derived organoids (PDOs) have improved predictive power, enabling them to reveal insights traditional 2D cell models lack.. However, their utility is currently limited by the lack of standardized assays with proven applicability for the pharmaceutical industry and the difficulty in producing PDOs in sufficient quantity, with the required quality and reproducibility.
Download this application note now to learn more about a unique bioprocess for the largescale expansion of 3D patient-derived organoids.
